

UTILITY PATENT APPLICATION TRANSMITTAL Only for new nonprovisional applications under 37 CFR 1.53(b)	Attorney Docket No.	7568M			
	First Inventor or Application Identifier	Mario Elam Tremblay			
	Title	METHOD FOR REMOVAL OF NANO PATHOGENS FROM LIQUIDS			
	Express Mail Label No.	EJ302200802US			
APPLICATION ELEMENTS See MPEP Chapter 600 concerning utility patent application contents.		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231			
1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)		5. <input type="checkbox"/> Microfiche Computer Program (Appendix)			
2. <input checked="" type="checkbox"/> Specification Total Pages [13] (preferred arrangement set forth below) <ul style="list-style-type: none">- Descriptive Title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R&D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claim(s)- Abstract of the Disclosure		6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ul style="list-style-type: none">a. <input type="checkbox"/> Computer Readable copyb. <input type="checkbox"/> Paper Copy (identical to computer copy)c. <input type="checkbox"/> Statement verifying identity of above copies			
3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) Total Sheets [2]		ACCOMPANYING APPLICATION PARTS 7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee) 9. <input type="checkbox"/> English Translation Document (if applicable) 10. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations 11. <input type="checkbox"/> Preliminary Amendment 12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 13. <input type="checkbox"/> *Small Entity <input type="checkbox"/> Statement filed in prior application Statement(s) Status still proper and desired 14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 15. <input type="checkbox"/> Other:			
4. Oath or Declaration Total pages [2] <ul style="list-style-type: none">a. <input checked="" type="checkbox"/> Newly executed (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 16 completed)i. <input type="checkbox"/> <u>DELETION OF INVENTORS</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b).					
* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37. C.F.R. §1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. §1.28).					
16. If a CONTINUING APPLICATION , check appropriate box and supply the requisite information below and in the preliminary amendment: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No. <u>1</u> Prior application information: Examiner: _____ Group/Art Unit: _____ For CONTINUATION or DIVISIONAL only: The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.					
17. CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number or Bar Code Label		(Insert Customer No. or Attach bar code label here)		<input type="checkbox"/> Correspondence address below	
NAME	Carl J. Roof The Procter & Gamble Company				
ADDRESS	Health Care Research Center 8700 Mason Montgomery Road				
CITY	Mason	STATE	OH	ZIP CODE	45040
COUNTRY	USA	TELEPHONE	513-622-3950	FAX	513-622-3300
Name (Print/Type)	Carl J. Roof		Registration No. (Attorney/Agent)	37,708	
Signature	<i>Carl J. Roof</i>		Date	May 19, 2000	

METHOD FOR REMOVAL OF NANO-SIZED PATHOGENS FROM LIQUIDS

Mario E. Tremblay

Steve G. Fishter

Dimitris I. Collias

5

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 60/135,083, filed May 20, 1999.

TECHNICAL FIELD

10 The present invention relates to the use of filters capable of removing nano-sized pathogens, including viruses, from liquids by filtration. In particular, it relates to the use of filters that comprise activated carbon particles for removing viruses from liquids.

BACKGROUND OF THE INVENTION

Water may contain many different kinds of nano-sized pathogens such as viruses.
15 In a variety of circumstances, these viruses must be removed before the water can be used. However, despite modern water purification means, the general population is at risk, and in particular infants and persons with compromised immune systems are at considerable risk. Breakdown and other problems with water treatment systems sometimes lead to incomplete removal of potential pathogens. There are deadly consequences associated with exposure
20 to contaminated water, as some countries have increasing population densities, increasingly scarce water resources, and no water treatment utilities. It is common for sources of drinking water to be in close proximity to human and animal waste, such that microbiological contamination is a major health concern. As a result of waterborne microbiological contamination, an estimated six million people die each year, half of which
25 are children under 5 years of age.

In the U. S., the National Sanitation Foundation (NSF), based on Environmental Protection Agency (EPA) studies, introduced standards that must be met for drinking water. The purpose of these standards is to establish minimum requirements regarding the performance of drinking water treatment systems that are designed to reduce specific health
30 related contaminants in public or private water supplies. Established in 1991, Standard 55 requires that the effluent from a water supply source exhibit 99.99% removal of viruses

against a challenge. As a representative microorganism for nano-sized pathogens, MS-2 bacteriophage is typically used because its size and shape (i.e., 25 nm and spherical) make it a particularly difficult microorganism to be removed from liquids, relative to nano-sized pathogens such as viruses. Thus, a filter's ability to remove MS-2 bacteriophage demonstrates its ability to remove nano-sized pathogens, such as viruses.

Therefore there is a need for a filter capable of removing a broad spectrum of nano-sized pathogens such as viruses. This filter would comprise a single, small, lightweight, self-contained system rather than a complex multi-component and/or multistage system to remove the various viruses. Such a filter would not only be more reliable than a complex system, but it would also be far more portable and economical. Thus, it could be utilized as a simple device on faucets in domestic settings where well water or water from a municipal source is used. In another application, such a device could be utilized in lesser developed regions of the world on a faucet or container for storing drinking water, where communal water sources are shared, but little is done to treat the water for contamination. A small, inexpensive, easy-to-use, water filter would be of great humanitarian value. In certain applications, the filter should present a low resistance to the flow of water so that in locations where electricity necessary to drive a pump may be unavailable, the filter may simply be connected between upper and lower containers of water, or between the holding container and a drinking receptacle. In certain embodiments, the filter should also have sufficient structural integrity to withstand significant pressures if, for example, a source of pressure is available to drive the liquid through the filtering apparatus (e.g. mechanical pump, faucet pumped water, etc.).

Despite centuries of a well-recognized need and many development efforts, activated carbon in its various forms has never been shown to reliably remove nano-sized pathogens from water or enjoyed wide-spread commercial use for nano-sized pathogen removal per se. Many attempts have been made over the years to apply activated carbon to pathogen removal without notable success. In the United States, the patent literature reflects that improved activated carbon particles and water treatment structures have been sought for water purification since at least the 1800's. For example, U. S. Pat. No. 29,560 (Belton, issued August 14, 1860) teaches that an adsorptive carbon can be made by combining peat, cut out of the bog, with chalk in water to make a paste, followed by molding and firing. U. S. Pat. No. 286,370 (Baker, issued October 9, 1883) teaches that artificial bone black blocks made from a slurry of finely powdered charred bones and magnesia can be used to good effect in water filters. The U. S. EPA has taught against the

use of activated carbon alone for nano-sized pathogen removal, stating that “activated carbon [even] with silver does not remove all viruses from water” (see 59 Federal Register 223, November 21, 1994).

While prior art references have previously utilized activated carbon in water filters,
5 it is evident that the activated carbon is being employed to remove organic and inorganic chemical matter. Thus, to the extent that certain prior art references disclose the use of activated carbon to treat a water source with respect to pathogen removal, including viruses, such approaches require the use of additional treatment steps or they require a relatively complex assembly of components.

10 In view of the foregoing, it has now been surprisingly discovered that a filter comprising activated carbon particles alone can reliably remove nano-sized pathogens from water. Accordingly, an object of the present invention is to provide a method for removing nano-sized pathogens from a water source. A specific object includes use of a water filter which removes nano-sized pathogens from the water source. The removal of such
15 pathogens using such a filter is at a level not previously demonstrated by the prior art. Such a filter will preferably present a low resistance to the flow of liquid through it, and will remove the pathogens from a substantial volume of water before becoming saturated. In certain embodiments, the filter will also preferably be relatively portable.

SUMMARY OF THE INVENTION

20 The invention relates to a method of removing nano-sized pathogens from a liquid, the method comprising contacting the liquid with a filter comprising activated carbon particles wherein said filter has a Pathogen Removal Index (“PRI”, determined according to the test method section below) of at least about 99.99%.

The invention further relates to an article of manufacture comprising:

- 25 (a) a filter comprising activated carbon particles, wherein said filter has an PRI of at least about 99.99%; and
- (b) information which communicates to a user that the filter may be used to remove nano-sized pathogens from a liquid.

BRIEF DESCRIPTION OF THE DRAWINGS

30 Figure 1 is a representation of the flow paths of viruses between activated carbon particles.

Figure 2 is a representation which illustrates the packing facilitated by use of

activated carbon particles of differing size.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

I. Definitions

As used herein, “Activated Carbon Particles” (ACP) mean activated carbon in any
5 form such as granular, spherical, pelleted, irregular shapes or other particles coated with
activated carbon.

As used herein, a “filter” is any article of manufacture containing the ACP to
enable its function in removing nano-sized pathogens from liquid. Such a filter may be as
simple as the ACP and an enclosure means to retain the ACP. It is apparent that such an
10 enclosure must be capable of preventing loss of ACP during operation, as well as
maintaining the desired inter-particle network during use.

As used herein, the terms “filters” and “filtration” refer primarily to removal via
adsorption.

As used herein, the terms liquid and water are used interchangeably.

15 As used herein, the term “nano-sized pathogens” refers to pathogens ranging in size
from about 20 nm to about 500 nm.

II. Activated Carbon Particles

Activated carbon particles can be characterized by their size, porosity, and specific
surface area. Size is meant to describe the longest dimension of the particle. Porosity is
20 characterized by the mean pore size of the particles. Specific surface area is a measure of
the particle surface area, including the area within the pores, per unit of mass of particle.
For the present invention, ACP will preferably have: specific surface areas in a range of
from about 100 to about 4000 m²/g, more preferably from about 500 to about 3000 m²/g,
still more preferably about 1000 to about 2500 m²/g; sizes in a range of from about 0.1 to
25 about 5000 µm, more preferably about 1 to about 1000 µm, still more preferably about 4 to
about 275 µm; and pore sizes from about 2.5 Å to about 300 nm, more preferably from
about 5 Å to about 200 nm, still more preferably from about 10 Å to about 100 nm.

III. Filters

A. Structures

30 Bulk density is commonly used in the art to describe carbon-containing structures.
The filters of the present invention will have a bulk density of from about 0.1 to about 1.2
g/cm³, preferably from about 0.4 to about 1.0 g/cm³, still more preferably about 0.6 to about

0.8 g/cm³. In having calculated the bulk density and knowing the dimensions of the activated carbon particles one can determine the average interstitial spacing between particles. Applicants have discovered that interstitial spacing between particles (also called inter-particle spacing or distance) is the critical parameter which controls the removal of nano-sized pathogens.

While not wishing to bound by theory, it is believed that the surprising ability of the present filters to remove nano-sized pathogens, particularly viruses, is due to inter-particle spacing that results from the packing of the activated carbon particles. It is believed that the attachment of nano-sized pathogens, and in particular viruses, onto activated carbon particles is governed by electrostatic, van der Waals, and hydrophobic forces. These forces have different signs, or equivalently, some of them are attractive and some repulsive. For example, the electrostatic forces are typically repulsive since most of the surfaces are negatively charged (except for modified surfaces as well as some unmodified clay structures and asbestos). On the other hand, van der Waals and hydrophobic forces are typically attractive. The net effect of all these forces is typically a minimum in the interaction energy, called secondary minimum, that causes nano-sized pathogens to attach to surfaces. In terms of interaction distances, electrostatic forces have a characteristic distance of about 50 nm, whereas van der Waals forces have a characteristic distance of about 100 nm. In addition to the above forces, some nano-sized pathogens, due to their structural characteristics, contain polymeric outer shells and in some cases appendages of various lengths. Furthermore, some nano-sized pathogens excrete various polymeric substances during their metabolic cycle that is believed to cause strengthening of the attachment as well as increase in the attachment sites for nano-sized pathogens that follow them.

With reference to Figure 1, in terms of the mechanics of the flow of pathogens in the filter, it is believed that the distance between two adjacent particles, c , is critical in achieving attachment of pathogens to the particles. In general, pathogens might flow close to the surface of a particle so that the overall attractive force would cause them to attach to the surface (see pathogen *A* in Figure 1). On the other hand, pathogens might flow far away from the particle surface so that the overall attractive force cannot "pull" them towards the particle surface for attachment (see pathogen *B* in Figure 1).

In terms of the effect of the inter-particle distance (also called spacing) on pathogen attachment onto the particle surface, it is believed that there is an optimum range of inter-particle distances that is necessary for pathogen attachment to particles and removal from

water. When this inter-particle distance, c (see Figure 1), is relatively large, then the majority of pathogens do not come sufficiently close to the particle surface for the forces mentioned above to cause attachment to the surface. As a result, the majority of pathogens do not get removed from the incoming water, and thus behave as pathogen *B* in Figure 1.

5 On the other hand, when this inter-particle distance is relatively small, the majority of pathogens come close to the surface of the particle and experiences the forces mentioned above. However, the shear conditions at these small gaps are high, and it is expected that the shear forces are high enough to overcome the attractive forces between pathogen and carbon surfaces. In these conditions there might be some pathogens that behave like

10 pathogens *A* in Figure 1 that do get attached to the particles. However, it is expected that due to high shear forces these pathogens might experience dislodging at some later point in time. As a result, the majority of pathogens do not get removed from the incoming water. Therefore, there is an optimum range of inter-particle spacing that strikes a balance between shear forces, attractive and repulsive forces. This balance ensures that pathogens

15 get removed during their flow in the carbon particle filters. Note that it is believed that the above described mechanism is applicable when the carbon surfaces have been modified, either chemically or physically, by adsorption of various compounds.

One process for building an activated carbon particle filter capable of removing nano-sized pathogens from a liquid comprises activated carbon particles extruded into the

20 form of a hollow tube. An example of such an extrusion process is described in U. S. Pat. No 5,331,037 (Koslow, July 19, 1994) and U.S. Pat. No. 5,189,092 (Koslow, Feb. 23, 1993). EP 792 676 A1 (Koslow, published 3/9/97) describes the properties of a filter made via such a process. The disclosure of each of these references is incorporated by reference. Importantly, EP 792 676 A1 does not teach or suggest that the disclosed extruded activated

25 carbon filters are capable of removing nano-sized pathogens from water. In fact, the reference discloses that the filters are only capable of removing up to 99.9% of particulates having a size of at least 500 nm.

Further and optionally, the carbon particles may be selected from a range of sizes so that when placed together, the inter-particle spacing between the first, and larger, size

30 particles will closely conform to the second, and smaller, size particles, and so that successively smaller size particles will closely conform with the remaining interstitial space between the various selected larger particles. By the selection of particle sizes and forms, the interstitial space can be substantially controlled and made uniform at a smaller scale than would be possible if a single particle size is used. Additionally, the activated carbon

particles may be combined with other particles, optionally of different shapes, to control inter-particle spacing. Such particles may be carbonaceous or non-carbonaceous.

In one embodiment illustrated in Figure 2, the activated carbon filter may be comprised of aligned larger particles compressed with a plurality of smaller particles so that the smaller particles fill in the interstitial space between the large particles, forming successively smaller and parallel interstitial spaces along the axis of the particles and continuous in the axial particles direction through the entire structure. In this embodiment it can be seen that the size of the interstitial spaces created is much smaller than that achieved with uniform sized particles. Thus, the inter-particle spacing can be controlled by the sizes or size distribution of the particles selected.

B. Pathogen Removal Properties

The method of the present invention relates to the removal from a water source of at least about 99.99% of nano-sized pathogens. That is, the method relates to the use of a filter that exhibits a Pathogen Removal Index ("PRI") of at least about 99.99%. Preferably, the filter will have a PRI of at least about 99.999%, more preferably at least about 99.9999%. Preferably, the filters will have a PRI of from about 99.99% to about 99.9999%.

The method of the present invention also relates to the removal from a water source at least about 99.99% of viruses. That is, the method includes the use of a filter that exhibits a Virus Removal Index ("VRI") of at least about 99.99%. Preferably, the filter will have a VRI of at least about 99.999%, more preferably at least about 99.9999%. Preferably, the filters will have a PRI of from about 99.99% to about 99.9999%.

The article of manufacture of the present invention comprises:

- (a) a filter comprising activated carbon particles, wherein said filter has a PRI or a VRI of at least about 99.99% (preferably the PRI or VRI will be about 99.999%, more preferably at least about 99.9999%); and
- (b) information which communicates to a user that the filter may be used to remove nano-sized pathogens, especially viruses, from a water source.

It is evident that the filters and methods described herein allow the treatment of water in excess of the standards set forth by the EPA in the U. S. In addition, applicants have found that the use of the filters described herein may be used for long periods of time without becoming exhausted in terms of the ability to continue to remove nano-sized pathogens from the source stream. The use of such filters therefore would improve the health risk situation in many countries, based on the fact that the population in general

would have less exposure to the various nano-sized pathogens, particularly viruses. Perhaps more importantly, in those geographies where contamination of the source water is significantly worse than that observed in more developed countries, the benefits provided by the present invention are magnified. For example, the ability to remove nano-sized pathogens at such a high level for such a long period of usage (i.e., before they reach failure because of saturation with the various nano-sized pathogens) allows for the purification, in terms of making water potable without undue health risk, of highly contaminated water.

C. Other Filter Components

As indicated, the filter will also include a housing for containing the activated carbon particles. A pre-filter can be used to provide particulate filtration of suspended solids that exceed 1 μm in size. A biocidal agent, such as silver, can be used to prevent biofilm formation with the filter system.

In one embodiment, the filter will comprise a housing containing a generally cylindrical filter arrangement. The housing has a liquid inlet and a liquid outlet and defines a liquid flow path between the inlet and outlet. The ACP arrangement is disposed within the housing in the liquid flow path and comprises a cylindrically shaped porous structure for removing particulate contaminants, chemical contaminants and microbiological contaminants from the liquid. The filter also includes impervious end members mounted to the ends of the filter arrangement, one of the end members having a central aperture. These end members direct liquid flow through the filter.

D. Articles of Manufacture

The present invention in another aspect comprises an article of manufacture comprising the ACP-containing filter and information that will communicate to the consumer, by words and/or by pictures, that use of the filter will provide water filtration benefits which include removal of nano-sized pathogens, particularly viruses, and this information may include the claim of superiority over other filter products. In a highly desirable variation, the article of manufacture bears the information that communicates to the consumer that the use of the filter provides reduced levels of nano-sized pathogens, including viruses. Accordingly, the use of packages in association with information that will communicate to the consumer, by words and/or by pictures, that use of the filter will provide benefits such as improved reduction of water contaminants as discussed herein, is important. The information can include, e.g., advertising in all of the usual media, as well as statements and icons on the package, or the filter itself, to inform the consumer.

IV. Test Methods For Measuring Pathogen and Virus Removal Indices

The following is a description of the methods for assessing a filter's ability to remove pathogens (i.e., its Pathogen Removal Index), including viruses (i.e., its Virus Removal Index), when exposed to a challenge consisting of water containing nano-sized pathogens.

A. Filtration Protocol

Test fluid in the form of dechlorinated water containing nano-sized microorganism is flowed through the filter at a rate of 100 ml per min for a period of 6 hours. The test fluid contains MS-2 bacteriophage (American Type Culture Collection (ATCC); Rockville, MD; ATCC# 15597B). The target concentration in the test fluid influent, based on the dilution from a concentrated stock, is 5×10^8 MS-2 bacteriophages/L.

B. Assay Conditions for Determining Pathogen and Virus Removal Indices

The assay used to calculate the influent and effluent concentration and thus the PRI and VRI is performed as follows. Bacteriophage MS-2 is serially diluted in Tris Buffered Saline (TBS; Trisma Inc., St. Louis, MO). The serial dilution is performed by taking 0.3 ml of influent or effluent and adding to 2.7 ml of TBS. The dilution is continued until a 10^{-4} dilution is produced. Then, the 3 ml dilution is added to 3 ml of molten (46°C) top agar (tryptic soy broth) with 1% Bacto agar, (Difco, Becton/Dickinson, Inc, Spark, MD) containing 0.1 ml of log-phase culture of *E. coli* host (ATCC# 15597). The suspension is vortexed and poured onto solid tryptic soy agar plates. The tryptic soy agar (Difco) is prepared by adding 40 g of the powder to 1 L of purified water in a 2 L Erlenmeyer flask set on a stir/hot plate. A 2 in. x $\frac{1}{2}$ in. stir bar is added to the Erlenmeyer flask and the stir/hot plate is turned up to a medium setting. The tryptic soy agar solution is mixed thoroughly on the stir/hot plate and heated to boiling for 1 minute. The solution is then autoclaved for 15 minutes at 121°C . Then 15 ml of the tryptic soy agar is poured into a 92 mm x 16 mm sterile Petri dish then cooled to produce the solid tryptic soy agar plate. The solid tryptic soy agar plates along with the top agar solution that has been added is incubated for 18-24 hours at 37°C and then enumerated by counting plaques formed on the lawn of host *E. coli* cells.

The Virus Removal Index is calculated as a percentage using the following equation:

$$VRI = [1 - (\text{Virus Effluent Conc./Virus Influent Conc.})] \times 100$$

The PRI is calculated by substituting the specific pathogen concentration for the virus concentration.

V. Example

5 A filter core (KX Industries #20-185-125-083, KX Industries, L.P., Orange, CT) is inserted into a filter housing (USWP#1A). The filter housing is connected to an EXPERT Peristaltic pump (model CP-120; by Scilog, Inc., Madison, Wisconsin) using Pharmed tubing (1/4 in. ID with 1/16 in. wall thickness).

One hundred liters of water to be used as influent is dechlorinated and sterilized
10 and stored in a 30 gallon carboy set on top of a stirring plate. The MS-2 bacteriophage (ATCC# 15597B) is seeded into the influent as the influent is mixed with a 2 in. by 1/2 in. stir bar stirred by the stirring plate set on maximum speed. The target concentration in the influent, based on the dilution from a concentrated stock, is 5×10^8 MS-2 bacteriophages per liter. A 50 ml sample of influent is collected into a 50 ml graduated conical centrifuge tube
15 for assay of MS-2. Once the seeded influent water is passed through the test unit for 1 hour at the prescribed flow rate (i.e., 1.1 L/min), 50 ml of effluent is collected into a 50 ml graduated conical centrifuge tube for assay of MS-2 bacteriophage. One ml of influent and effluent is needed to perform an assay of MS2 bacteriophage. Seeded influent water is pumped at the prescribed flow rate (i.e., 1.1 L/min) through the test units until the next
20 sampling time point. An adjacent 30 gallon carboy is filled with seeded MS-2 bacteriophages as previously described. The Pharmed tubing used to draw the influent from the carboy is transferred to the adjacent carboy when only 10 L of influent remain in the original 30 gallon carboy.

Effluent is then collected at each sampling time point (i.e., 1, 6 and 10 hours) at the
25 volumes previously described to assay the MS-2 bacteriophages according to Section IV-B. As a result, a VRI of 99.9999% is obtained at 1.1 L/min after 10 hours. The test units are un-clamped from the testing stand and disconnected from the Pharmed tubing after the last sampling time point is reached (i.e., 10 hours). The test units are then autoclaved after the analysis is completed.

30

WHAT IS CLAIMED IS:

1. A method of removing nano-sized pathogens from a liquid, the method comprising contacting the liquid with a filter comprising activated carbon particles wherein said filter has a Pathogen Removal Index (PRI) of at least about 99.99%.

2. The method of Claim 1 wherein the filter has a PRI of at least about 99.999%.

3. The method of Claim 2 wherein the filter has a PRI of at least about 99.9999%.

4. A method of removing viruses from a liquid, the method comprising the steps of contacting the liquid with a filter comprising activated carbon particles wherein said filter has a Virus Removal Index (VRI) of at least about 99.99%.

5. The method of Claim 4 wherein the filter has a VRI of at least about 99.999%.

6. The method of Claim 5 wherein the filter has a VRI of at least about 99.9999%.

7. The method of Claim 4 wherein the filter comprises activated carbon particles having inter-particle spacings that result in a bulk density of from about 0.6 to about 0.8 g/cm³.

8. The method of Claim 7 wherein a mixture of activated carbon particles of different size and/or shape are utilized.

9. An article of manufacture comprising:

(a) a filter comprising activated carbon particles, wherein said filter has a PRI of at least about 99.99%; and

(b) information which communicates to a user that the filter may be used to remove nano-sized pathogens from a liquid.

10. The article of Claim 9, wherein the filter has a PRI of at least about 99.999%.

11. The article of Claim 10, wherein the filter has a PRI of at least about 99.9999%.

12. An article of manufacture comprising:

(a) a filter comprising activated carbon particles, wherein said filter has a VRI of at least about 99.99%; and

(b) information which communicates to a user that the filter may be used to remove nano-sized pathogens from a liquid.

13. The article of Claim 12, wherein the filter has a VRI of at least about 99.999%.

14. The article of Claim 13, wherein the filter has a VRI of at least about 99.9999%.

15. The article of Claim 12 wherein the filter comprises activated carbon particles having inter-particle spacings that result in a bulk density of from about 0.6 to about 0.8 g/cm³.

16. The article of Claim 12 wherein a mixture of activated carbon particles of different size and/or shape are utilized.

METHOD FOR REMOVAL OF NANO-SIZED PATHOGENS FROM LIQUIDS

Mario E. Tremblay

Steve G. Fishter

Dimitris I. Collias

ABSTRACT OF THE DISCLOSURE

Disclosed is a method of removing nano-sized pathogens, including viruses, from a liquid, the method comprising contacting the liquid with a filter comprising activated carbon particles wherein said filter has a Pathogen Removal Index of at least about 99.99%.

Also disclosed is an article of manufacture comprising:

- (a) a filter comprising activated carbon particles, wherein said filter has a Pathogen Removal Index of at least about 99.99%; and
- (b) information which communicates to a user that the filter may be used to remove nano-sized pathogens from a liquid.

"Express Mail" mailing label number EJ302200802US


Date of Deposit May 11 2000

I hereby certify that this paper/fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231


Carl J. Roof 37,708
Attorney mailing application Reg No

Carl J. Roof
Signature of Attorney mailing application

1/2



2/2



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Method for Removal of Nano-Sized Pathogens from Liquids
the specification of which

(check one) ☒ is attached hereto.
☐ was filed on _____ as United States Application No. or
PCT International Application Serial No. _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56.

I hereby claim foreign priority benefits under Title 35 United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Serial No.	Filing Date	Application Serial No.	Filing Date

I hereby claim the benefit under Title 35 United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35 United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (If applicable)

As named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Atty Name	Atty Reg Number.	Associate Power of Attorney Attached
Carl J. Roof	37,708	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
David L. Suter	30,692	
Jacobus C. Rasser	37,043	
T. David Reed	32,931	
Timothy B. Guffey	41,048	
Eileen L. Hughett	34,352	
Emelyn L. Hiland	41,501	
Linda M. Sivik	44,982	

SEND CORRESPONDENCE TO:

Attorney or Agent's Name: Carl J. Roof

The Procter & Gamble Company (513) 622-3950

Company Name	Phone No.
8700 Mason Montgomery Road Cincinnati Ohio 45040	
Street City State Zip Code	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Mario Elam Tremblay

Inventor's signature _____
Date _____

Residence 7897 Woodglen Drive West Chester, OH 45069

Citizenship Canadian

Post Office Address The Procter & Gamble Company
8700 Mason Montgomery Road Mason, OH 45040

Full name of second joint inventor, if any Steve Gary Fishter

Inventor's signature _____
Date _____

Residence 310 Broadway Harrison, OH 45030

Citizenship US

Post Office Address The Procter & Gamble Company
8700 Mason Montgomery Road Mason, OH 45040

Full name of third joint inventor, if any Dimitris Ioannis Collias

Inventor's signature _____
Date _____

Residence 4683 Cedar Village Drive Mason, OH 45040

Citizenship US

Post Office Address The Procter & Gamble Company
8700 Mason Montgomery Road Mason, OH 45040

Full name of fourth joint inventor, if any _____

Inventor's signature _____
Date _____

Residence _____

Citizenship _____

Post Office Address _____
